Merck is committing $4 billion upfront to team up with Daiichi Sankyo on a trio of antibody-drug conjugates, adding fuel to a space that’s heating up on blockbuster revenue, data readouts and a flurry of M&A.
All three programs the two companies will be co-developing and…
Click here to view original post
